Clinical trials: Systemic Lupus Erythematosus (SLE)
Lupus Erythematosus, Systemic, Coronary Artery Disease
CMR-Lupus Comprehensive Approach by Cardiovascular Magnetic Resonance Tomography
In systemic lupus erythematosus (SLE), cardiac manifestations, e.g. coronary artery disease (CAD) and myocarditis are leading causes of morbidity and mortality. The prevalence of subclinical heart disease in SLE is unknown.
- Conditions
- Lupus Erythematosus, Systemic, Coronary Artery Disease, Myocardial Disease
- Trial name
- NCT03488654
- Testing
- Cardiovascular magnetic resonance
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University Hospital, Basel, Switzerland
Systemic Lupus Erythematosus, Lupus Nephritis
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Trial name
- NCT06121297
- Testing
- CABA-201
- Where
- 23 sites in United States, Canada and 1 more
- Volunteers
- 28 people
- Sponsor
- Cabaletta Bio
Systemic Lupus Erythematosus, Lupus Nephritis
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
This study is a preliminary investigation, with a single-group design, not randomized and transparent, focusing on treatment. Its purpose is to identify the highest dose of BH002 injection (CD19-BCMA CAR-T cells) that patients…
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Autoimmune Diseases, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- BAH242 (NCT06350110)
- Testing
- CD19- BCMA CAR-T cells
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Essen Biotech
Lupus Erythematosus, Systemic
Synergetic B-cell Immunomodulation in SLE - 2nd Study.
In follow-up of the previous SynBioSe Study the present study is a randomized controlled trial designed to further investigate the long-term clinical and imunological efficacy of combination B-cell targeting by starting treatment…
- Trial name
- SynBioSe-2 (NCT03747159)
- Testing
- Belimumab Injection
- Where
- 4 sites in Netherlands
- Volunteers
- 71 people
- Sponsor
- Leiden University Medical Center
Lupus Erythematosus
Identification of Modifiable Sleep-related Factors in Patients With Systemic Lupus Erythematosus.
Background: Sleep quality is a key determinant of physical and mental health, with important implications for immune regulation, psychological well-being, and overall quality of life.
- Trial name
- NCT07483541
- Testing
- Adults with systemic lupus erythematosus
- Where
- Spain
- Volunteers
- 250 people
- Sponsor
- Investigación en Hemofilia y Fisioterapia
Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia (AIHA)
Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)
This is an open lable and single arm study designed to evaluate the safety, PK and PD of Arnovie101 in B cell-mediated Autoimmune Disease
- Trial name
- NCT07629596
- Testing
- Arnovie101 Infusion Intravenous
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Circunited BioPharma (Shenzhen) Co., Ltd.
Fatigue, Systemic Lupus Erthematosus
Fatigue in Systemic Lupus Erythematosus
The aim of this study is to investigate the effects of biopsychosocial status, quality of life, functional status and hematological markers on fatigue in individuals with SLE.
- Trial name
- NCT06652256
- Where
- Turkey (Türkiye)
- Volunteers
- 39 people
- Sponsor
- Pamukkale University
Glucocorticoids Toxicity, Rheumatoid Arthritis
Monıtorıng Glucocortıcoıd Treatment In Patıents Followed In Rheumatology Clınıc
Hypothesis 1: A reduction in side effects is achieved with monitoring glucocorticoid treatment by using the Glucocorticoid Toxicity Index (GTI) in patients using glucocorticoids.
- Conditions
- Glucocorticoids Toxicity, Rheumatoid Arthritis, Vasculitis, Systemic Lupus Erythematosus
- Trial name
- NCT05292456
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Hacettepe University
Refractory Systemic Lupus Erythematosus
IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)
The study is a single-arm, open-label clinical trial intended to recruit 6 refractory SLE subjects who meet the inclusion and exclusion criteria.
- Trial name
- NCT06513429
- Testing
- IM19 CAR-T cells
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Peking University Third Hospital
Lupus Erythematosus, Systemic, Lupus Nephritis
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
The purpose of this study is to examine the safety of a single dose of RG2077 in patients with systemic lupus erythematosus (SLE) who are currently receiving cyclophosphamide.
- Trial name
- NCT00094380
- Testing
- CTLA4-IgG4m (RG2077), Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Lupus Erythematosus
Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care
This study will be conducted to assess the safety, tolerability, and immunogenicity of repeat doses of BOS161721 (20 milligrams [mg], 60 mg, and 120 mg) administered subcutaneously in adult participants with moderately to…
- Trial name
- NCT03371251
- Testing
- BOS161721
- Where
- 68 sites in United States, Argentina and 10 more
- Volunteers
- 143 people
- Sponsor
- Boston Pharmaceuticals
Systemic Lupus Erythematosus, Lupus Nephritis
Epigenetics in Lupus Nephritis
This is a translational study for the identification of epigenetic changes detectable in sera of patients suffering from Systemic Lupus erythematosus.
- Trial name
- Epi_LN (NCT04648059)
- Testing
- Blood sampling
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University of Göttingen
Rheumatoid Arthritis, Pemphigus Vulgaris
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
This study will evaluate the safety and activity of AB-101 in combination with rituximab in B-cell associated autoimmune diseases where rituximab is currently FDA approved (e.g., Rheumatoid Arthritis (RA), Pemphigus Vulgaris…
- Conditions
- Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus
- Trial name
- IRIS-RD-01 (NCT06581562)
- Testing
- AB-101, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- IRIS Research and Development, LLC
Facial Telangiectasia in Patients With Systemic Lupus Erythematosus
Efficacy of Intense Pulsed Light in the Treatment of Facial Telangiectasia in Systemic Lupus Erythematosus
This clinical trial intends to evaluate the efficacy and safety of intense pulsed light (IPL) in the treatment of facial telangiectasia in patients with systemic lupus erythematosus (SLE).
- Trial name
- NCT04717583
- Testing
- Intense pulsed light (IPL) treatment
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Second Xiangya Hospital of Central South University
Systemic Lupus Erythematosus
Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus
In China, Belimumab (GSK1550188) will be developed for a dosing regimen of once-monthly intravenous (IV) infusion for the treatment of SLE.
- Trial name
- NCT02880852
- Testing
- Belimumab
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Lupus Erythematosus, Systemic
Positron Emission Tomography (PET) to Locate Areas of White Blood Cell Activity
This study will examine whether PET imaging can reveal what is happening in lymph nodes of patients with systemic lupus erythematosus, or lupus, during periods of active disease.
- Trial name
- NCT00029926
- Testing
- 2-deoxy-2 [F-18] fluoro-2-d-glucose
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Systemic Lupus Erythematosus
Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus
The purpose of this study is to evaluate the safety and efficacy of repeated intravenous infusions of the study drug BT063 in patients with Systemic Lupus Erythematosus (SLE) compared with people who receive a placebo.
- Trial name
- BT063 in SLE (NCT02554019)
- Testing
- BT063
- Where
- 14 sites in Belarus, Georgia and 2 more
- Volunteers
- 36 people
- Sponsor
- Biotest
Systemic Lupus Erythematosus
Clinical Characteristics and Outcomes of SLE Patients Admitted to Critical Care Unit
The aim of the present work is to determine the frequency of critical complications of SLE patients admitted to the intensive care unit,study the risk factors and out comes.
- Trial name
- NCT05418855
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assiut University
Systemic Lupus Erythematosus (SLE), Lupus Nephritis
Detection of Annexin A2 in Systemic Lupus Erythematosus
There is substantial clinical and biological intra and inter-patient variability in SLE. Vascular, renal and neurologic deficiency can be organ-threatening or even life-threatening, leading to increased morbidity and mortality.
- Trial name
- ANLUP (NCT03031925)
- Testing
- ANXA2
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Systemic Lupus Erythematosus
Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem Cells
Treatment of systemic lupus erythematosus with pooled allogenic mesenchymal stem cells
- Trial name
- NCT04184258
- Testing
- Pooled mesenchymal stem cell, Standard treatment according to the Clinical protocols
- Where
- Belarus
- Volunteers
- 7 people
- Sponsor
- Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.